S&P Futures
3,918.75 +2.50 (+0.06%) Dow Futures
31,500.00 +13.00 (+0.04%) Nasdaq Futures
12,150.25 +9.75 (+0.08%) Russell 2000 Futures
1,762.80 +1.10 (+0.06%) Crude Oil
107.37 -0.25 (-0.23%) Gold
1,836.60 +6.30 (+0.34%)
Biotech Acquisition Company (BIOT)
Chart Events
Performance Outlook
| Previous Close | 9.80 |
| Open | 9.84 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 40000 |
| Day's Range | 9.82 - 9.84 |
| 52 Week Range | 8.30 - 10.41 |
| Volume | |
| Avg. Volume | 151,353 |
| Market Cap | 282.9M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.17 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BIOT
Related Research
- Biotech Acquisition CompanyDaily – Vickers Top Buyers & Sellers for 01/26/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
- American City Business Journals
The Funded: One Bay Area SPAC merger died as another headed to a vote
In more signs of trouble in the blank-check merger market, Blade Therapeutics cancelled its planned deal. Meanwhile another startup is preparing for a shareholder vote after offering a disappointing financial forecast.
- PR Newswire
Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement
Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the "Merger Agreement"), effective immediately.
- American City Business Journals
Senti Bio goes public to reprogram cells as self-driving cars in the body
Even as some SPACs get tripped up, Senti plans to use its merger to push two cell therapies into clinical trials, sign more deals with gene therapy companies and open a manufacturing center in Alameda.
